Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BIVINASDAQ:CMMBNASDAQ:DRMANASDAQ:LPCN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIVIBioVie$1.03$0.95$0.62▼$7.50$19.12M0.661.84 million shs88,634 shsCMMBChemomab Therapeutics$1.37+0.4%$1.20$0.78▼$2.55$19.60M0.55212,373 shs133,868 shsDRMADermata Therapeutics$0.74-3.3%$0.89$0.69▼$5.00$4.74M0.591.18 million shs31,161 shsLPCNLipocine$3.58-3.0%$3.27$2.68▼$11.79$19.15M1.5235,201 shs27,039 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIVIBioVie0.00%0.00%+15.19%-30.41%+112.72%CMMBChemomab Therapeutics0.00%-0.36%+5.81%-20.18%+62.50%DRMADermata Therapeutics0.00%-6.07%-0.93%-40.56%-79.48%LPCNLipocine0.00%-10.28%+12.58%+5.92%-45.76%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBIVIBioVie2.7171 of 5 stars3.84.00.00.03.30.00.6CMMBChemomab Therapeutics3.0288 of 5 stars3.55.00.00.01.31.71.3DRMADermata Therapeutics1.403 of 5 stars3.52.00.00.01.10.00.6LPCNLipocine1.9572 of 5 stars3.53.00.00.02.30.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIVIBioVie 3.50Strong Buy$3.00191.26% UpsideCMMBChemomab Therapeutics 3.00Buy$8.50522.71% UpsideDRMADermata Therapeutics 3.00Buy$3.00303.77% UpsideLPCNLipocine 3.00Buy$10.00179.33% UpsideCurrent Analyst Ratings BreakdownLatest DRMA, BIVI, CMMB, and LPCN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025DRMADermata TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $3.005/16/2025CMMBChemomab TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$11.00 ➝ $10.003/18/2025BIVIBioVieBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIVIBioVieN/AN/AN/AN/A$2.54 per shareN/ACMMBChemomab TherapeuticsN/AN/AN/AN/A$1.54 per shareN/ADRMADermata TherapeuticsN/AN/AN/AN/A$24.24 per shareN/ALPCNLipocine$3.67M5.21N/AN/A$3.83 per share0.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIVIBioVie-$32.12M-$7.91N/A∞N/AN/A-134.07%-93.44%N/ACMMBChemomab Therapeutics-$24.22M-$0.76N/AN/AN/AN/A-101.70%-76.18%N/ADRMADermata Therapeutics-$7.80M-$16.41N/A∞N/AN/A-247.39%-179.72%N/ALPCNLipocine-$16.35M-$1.02N/A∞N/AN/A-19.17%-17.60%8/6/2025 (Estimated)Latest DRMA, BIVI, CMMB, and LPCN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CMMBChemomab Therapeutics-$0.20-$0.14+$0.06-$0.14N/AN/A5/14/2025Q1 2025DRMADermata Therapeutics-$0.45-$0.45N/A-$0.45N/AN/A5/12/2025Q3 2025BIVIBioVie-$0.32-$0.15+$0.17-$0.15N/AN/A5/8/2025Q4 2024LPCNLipocine-$0.35-$0.35N/A-$0.35$0.35 million$0.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBIVIBioVieN/AN/AN/AN/AN/ACMMBChemomab TherapeuticsN/AN/AN/AN/AN/ADRMADermata TherapeuticsN/AN/AN/AN/AN/ALPCNLipocineN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIVIBioVieN/A16.9416.94CMMBChemomab TherapeuticsN/A4.574.57DRMADermata TherapeuticsN/A3.443.44LPCNLipocineN/A12.9712.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIVIBioVie4.59%CMMBChemomab Therapeutics46.05%DRMADermata Therapeutics8.67%LPCNLipocine9.11%Insider OwnershipCompanyInsider OwnershipBIVIBioVie4.00%CMMBChemomab Therapeutics11.91%DRMADermata Therapeutics9.40%LPCNLipocine6.12%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBIVIBioVie1018.56 million17.71 millionNo DataCMMBChemomab Therapeutics2014.36 million12.65 millionNot OptionableDRMADermata Therapeutics86.38 million1.85 millionNot OptionableLPCNLipocine105.35 million5.02 millionNo DataDRMA, BIVI, CMMB, and LPCN HeadlinesRecent News About These CompaniesLe LPCN 1148 de Lipocine mis en avant dans l'édition de juin 2025 de HepatologyMay 23 at 1:43 AM | zonebourse.comLipocine’s LPCN 1148 Gains Fast Track DesignationMay 22 at 10:33 AM | tipranks.comLipocine's LPCN 1148 Highlighted in the June 2025 Edition of HepatologyMay 22 at 8:00 AM | prnewswire.comStockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN)May 19, 2025 | americanbankingnews.comLipocine to Present at A.G.P. Healthcare ShowcaseMay 14, 2025 | tipranks.comLipocine to Present at A.G.P.'s Annual Healthcare Company ShowcaseMay 14, 2025 | prnewswire.comLipocine Reports Q1 2025 Financial ResultsMay 8, 2025 | tipranks.comLipocine Announces Financial Results for the First Quarter Ended March 31, 2025May 8, 2025 | prnewswire.comLipocine inks license and supply agreement for TLANDO in BrazilMay 7, 2025 | msn.comLipocine s’associe à Aché pour commercialiser TLANDO au BrésilMay 7, 2025 | fr.investing.comLipocine Inc. annonce un accord de licence et d'approvisionnement pour Tlando® au BrésilMay 7, 2025 | zonebourse.comLipocine Partners with Aché for TLANDO® in BrazilMay 6, 2025 | tipranks.comLipocine Announces License and Supply Agreement for TLANDO® in BrazilMay 6, 2025 | prnewswire.comL’action LPCN atteint son plus bas niveau sur 52 semaines à 2,91$April 7, 2025 | fr.investing.comLipocine Inc. Reports 2024 Financial TurnaroundApril 4, 2025 | tipranks.comLipocine’s Phase III trial of LPCN 1154 to begin for postpartum depressionMarch 27, 2025 | finance.yahoo.comLipocine initiates Phase 3 trial for LPCN 1154March 27, 2025 | markets.businessinsider.comLipocine annonce le début de l'étude de phase 3 en ambulatoire sur la dépression post-partum avec le LPCN 1154March 26, 2025 | zonebourse.comLipocine Inc. annonce le début de l'essai de phase 3 sur la dépression post-partum en consultation externe du LPCN 1154March 26, 2025 | zonebourse.comLipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154March 26, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDRMA, BIVI, CMMB, and LPCN Company DescriptionsBioVie NASDAQ:BIVI$1.03 0.00 (0.00%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.04 +0.01 (+1.46%) As of 05/23/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.Chemomab Therapeutics NASDAQ:CMMB$1.36 +0.01 (+0.37%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$1.42 +0.05 (+4.03%) As of 05/23/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.Dermata Therapeutics NASDAQ:DRMA$0.74 -0.03 (-3.26%) Closing price 05/23/2025 03:45 PM EasternExtended Trading$0.75 +0.01 (+0.94%) As of 05/23/2025 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.Lipocine NASDAQ:LPCN$3.58 -0.11 (-2.98%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$3.60 +0.02 (+0.42%) As of 05/23/2025 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
